5-amino-3,3-dimethyl-5-oxopentanoic acid | 92116-87-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-amino-3,3-dimethyl-5-oxopentanoic acid
• CAS: 92116-87-5
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: IWSBDEJUUPISJO-UHFFFAOYSA-N

物化性质

• 沸点：
  390.3±25.0 °C(Predicted)
• 密度：
  1.140±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-amino-3,3-dimethyl-5-oxopentanoic acid 在 lithium aluminium tetrahydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 lithium chloride 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 乙腈 为溶剂， 反应 39.0h， 生成 (E)-N-(8-diazo-3,3-dimethyl-7-oxooct-5-en-1-yl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  由N末端α，β-不饱和重氮酮快速合成双环N-杂环核

  摘要：

  描述了由N末端α，β-不饱和重氮酮合成双环N杂环核的方法。转化过程包括三步多米诺过程，涉及一个一锅N-脱保护，分子内氮杂迈克尔和光化学反应的Wolff重排序列。

  DOI：

  10.1002/ejoc.201800239
• 作为产物：
  描述：

  3,3-二甲基戊二酸酐 在 氨 作用下， 以 various solvent(s) 为溶剂， 生成 5-amino-3,3-dimethyl-5-oxopentanoic acid
  参考文献：
  名称：

  羧基官能团对铂蓝合成的分子内影响。对源自酰胺的配合物的系统研究

  摘要：

  使用 d'un amidoacide comme coordinat pour obtenir du bleu de Pt. On montre le role de la fonction carboxylique qui offre un site primaire de fixation a Pt. 活性抗肿瘤

  DOI：

  10.1021/ja00329a028

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS MÉTHODES D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2022056281A1

  公开（公告）日：2022-03-17

  Provided herein are compounds including compounds of formula (I), compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment,e.g., a cancer or a metabolic disease.

  本文提供了包括式(I)化合物在内的化合物、组合物和方法，用于抑制蛋白酪氨酸磷酸酶，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），并用于治疗与PTPN1或PTPN2抑制剂治疗有利响应的相关疾病、障碍和状况，例如癌症或代谢疾病。
• Heteroarylakanoic acids as intergrin receptor antagonists
  申请人：——

  公开号：US20040092497A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr; 3 and/or the &agr;&ngr;&bgr; 5 integrin without significantly antagonizing the IIb/IIIa integrin. 1

  本发明涉及一类由式（I）表示的化合物或其药学上可接受的盐、包含式（I）化合物的制药组合物以及选择性拮抗&agr;&ngr;&bgr;3和/或&agr;&ngr;&bgr;5整合素而不显著拮抗IIb/IIIa整合素的方法。
• Heteroarylalkanoic acids as integrin receptor antagonists
  申请人：——

  公开号：US20020133023A1

  公开（公告）日：2002-09-19

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &agr; V &bgr; 3 and/or the &agr; V &bgr; 5 integrin without significantly antagonizing the IIb/IIIa or &agr; V &bgr; 6 integrin.

  本发明涉及一类由式I1表示的化合物或其药学上可接受的盐，包括式I的药物组合物，并且涉及一种选择性拮抗&agr;V&bgr;3和/或&agr;V&bgr;5整合素而不显著拮抗IIb/IIIa或&agr;V&bgr;6整合素的方法。
• Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents
  作者：Ying Chang、Weiyi Pi、Wei Ang、Yuanyuan Liu、Chunlong Li、Jiajia Zheng、Li Xiong、Tao Yang、Youfu Luo

  DOI：10.1016/j.bmcl.2014.02.065

  日期：2014.4

  In this work, nineteen analogues of Agomelatine were readily synthesized through structural modification of the acetamide side-chain starting from the key common intermediate 2-(7-methoxynaphthalen-1-yl) ethanamine (3), which was prepared from commercially available compound 2-(7-methoxynaphthalen-1-yl) acetonitrile (2) in two steps. Corticosterone-induced PC12 pheochromocytoma cells phenotypic in vitro model was utilized to evaluate their potential antidepression activities. Imide compound 4a and acylamino carboxylic acid analogue 5b showed good protective effects on traumatic PC12 cells with protection rates of 34.2% and 23.2%, respectively. Further in vivo assessments in C57 mice FST (forced swim test) model demonstrated that compound 4a significantly reduced the immobility time of the tested subjects, indicating antidepressant- like activity. Preliminary toxicity assays conducted on human normal liver L02 cells and embryonic kidney 293 cells suggested a relatively low safety risk for compound 4a compared with the marketed drugs Agomelatine and Fluoxetine. The promising antidepressant-like efficacy of compound 4a, together with the relatively low toxicity to the normal tested cells and high liability of diffusion through the blood-brain barrier (BBB), presents us insights of exploration of me-better drug candidates of Agomelatine. (C) 2014 Elsevier Ltd. All rights reserved.
• The Preparation of Geminally Substituted 4-Bromobutylamines. II. 4-Bromo-2,2-dialkyl- and diarylbutylamines¹
  作者：Ronald F. Brown、Norman M. van Gulick

  DOI：10.1021/ja01610a002

  日期：1955.3